Zhang Ping-Ping, Guo Yan-Ting, Chu Yu-Qin, Ji Q I, Lian Yan, Li Wei, Yao Li-Na
Department of Pediatrics, Tianjin First Central Hospital, Tianjin 300190, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Jul 15;24(7):736-741. doi: 10.7499/j.issn.1008-8830.2204074.
To investigate the serum level of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific RBD IgG antibody (SARS-CoV-2 IgG antibody for short) in children with SARS-CoV-2 Omicron variant infection during the recovery stage, as well as the protective effect of SARS-CoV-2 vaccination against Omicron infection.
A retrospective analysis was performed on 110 children who were diagnosed with coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 Omicron variant infection in Tianjin of China from January 8 to February 7, 2022. According to the status of vaccination before diagnosis, they were divided into a booster vaccination (3 doses) group with 2 children, a complete vaccination (2 doses) group with 90 children, an incomplete vaccination (1 dose) group with 5 children, and a non-vaccination group with 13 children. The clinical data and IgG level were compared among the 4 groups.
The complete vaccination group had a significantly higher age than the non-vaccination group at diagnosis (<0.05), and there was a significant difference in the route of transmission between the two groups (<0.05). There were no significant differences among the four groups in sex, clinical classification, and re-positive rate of SARS-CoV-2 nucleic acid detection (>0.05). All 97 children were vaccinated with inactivated vaccine, among whom 85 children (88%) were vaccinated with BBIBP-CorV Sinopharm vaccine (Beijing Institute of Biological Products, Beijing, China). At 1 month after diagnosis, the booster vaccination group and the complete vaccination group had a significantly higher level of SARS-CoV-2 IgG antibody than the non-vaccination group (<0.05), and at 2 months after diagnosis, the complete vaccination group had a significantly higher level of SARS-CoV-2 IgG antibody than the non-vaccination group (<0.05). For the complete vaccination group, the level of SARS-CoV-2 IgG antibody at 2 months after diagnosis was significantly lower than that at 1 month after diagnosis (<0.05).
Vaccination with inactivated SARS-CoV-2 vaccine has a protective effect against Omicron infection in children. For children vaccinated with 2 doses of the vaccine who experience Omicron infection, there may be a slight reduction in the level of SARS-CoV-2 IgG antibody at 2 months after diagnosis. .
调查新型冠状病毒2(SARS-CoV-2)奥密克戎变异株感染儿童康复期血清中SARS-CoV-2特异性受体结合域IgG抗体(简称SARS-CoV-2 IgG抗体)水平,以及SARS-CoV-2疫苗对奥密克戎感染的保护作用。
对2022年1月8日至2月7日在中国天津被诊断为SARS-CoV-2奥密克戎变异株感染所致新型冠状病毒肺炎(COVID-19)的110例儿童进行回顾性分析。根据诊断前的疫苗接种情况,将其分为加强接种(3剂)组2例、全程接种(2剂)组90例、未完成接种(1剂)组5例和未接种组13例。比较4组的临床资料和IgG水平。
全程接种组诊断时年龄显著高于未接种组(<0.05),两组传播途径存在显著差异(<0.05)。4组在性别、临床分型及SARS-CoV-2核酸检测复阳率方面差异无统计学意义(>0.05)。97例儿童均接种灭活疫苗,其中85例(88%)接种的是国药集团中国生物北京生物制品研究所的BBIBP-CorV疫苗。诊断后1个月,加强接种组和全程接种组SARS-CoV-2 IgG抗体水平显著高于未接种组(<0.